RT Journal Article
T1 Percutaneous Mitral Valve Repair: Outcome Improvement with Operator Experience and a Second-Generation Device.
A1 Freixa, Xavier
A1 Estévez-Loureiro, Rodrigo
A1 Carrasco-Chinchilla, Fernando
A1 Millán, Xavier
A1 Amat-Santos, Ignacio
A1 Regueiro, Ander
A1 Nombela-Franco, Luis
A1 Pascual, Isaac
A1 Cid, Belen
A1 López-Mínguez, José Ramón
A1 Hernández-Antolín, Rosa Ana
A1 Cruz-González, Ignacio
A1 Andraka, Leire
A1 Goicolea, Javier
A1 Ruíz-Quevedo, Valeriano
A1 Díez, Jose Luís
A1 Berenguer, Alberto
A1 Baz, José Antonio
A1 Pan, Manuel
A1 Benito-González, Tomas
A1 Briales, Juan H Alonso
A1 Li, Chi Hion
A1 Sanchis, Laura
A1 Serrador, Ana
A1 Jiménez-Quevedo, Pilar
A1 Avanzas, Pablo
A1 Salido, Luisa
A1 Fernández-Vázquez, Felipe
A1 Hernández-García, José Maria
A1 Arzamendi, Dabit
K1 MitraClip
K1 mitral regurgitation
K1 transcatheter mitral valve repair
AB Recent randomized data comparing percutaneous mitral valve repair (PMVR) versus optimal medical treatment in patients with functional MR (FMR) seemed to highlight the importance of the learning curve not only for procedural outcomes but also for patient selection. The aim of the study was to compare a contemporary series of patients undergoing PMVR using a second-generation Mitraclip device (Mitraclip NT) with previous cohorts treated with a first-generation system. This multicenter study collected individual data from 18 centers between 2012 and 2017. The cohort was divided into three groups according to the use of the first-generation Mitraclip during the first (control-1) or second half (control-2) or the Mitraclip NT system. A total of 545 consecutive patients were included in the study. Among all, 182 (33.3%), 183 (33.3%), and 180 (33.3%) patients underwent mitral repair in the control-1, control-2, and NT cohorts, respectively. Procedural success was achieved in 93.3% of patients without differences between groups. Major adverse events did not statistically differ among groups, but there was a higher rate of pericardial effusion in the control-1 group (4.3%, 0.6%, and 2.6%, respectively; p = 0.025). The composite endpoint of death, surgery, and admission for congestive heart failure (CHF) at 12 months was lower in the NT group (23.5% in control-1, 22.5% in control-2, and 8.3% in the NT group; p = 0.032). The present paper shows that contemporary clinical outcomes of patients undergoing PMVR with the Mitraclip system have improved over time.
SN 2077-0383
YR 2021
FD 2021-02-12
LK https://hdl.handle.net/10668/27033
UL https://hdl.handle.net/10668/27033
LA en
DS RISalud
RD Apr 11, 2025